以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 自去年起，减重诊疗对公立医院来说，已经从"可选项"变成了必须认真布局的新任务。 2024年6月，国家卫生健康委联合16个部门发布了《"体重管理年"活动实施方案》，明确鼓励有条件的医疗卫生机构设立体重管理门诊。政策 要求，国家卫生健康委、国家中医药局直属及管理医院，以及各省（区、市）属综合医院、儿童医院、中医医院，要在2025年6月底前基本实 现体重管理门诊的全覆盖。 随着政策"最后期限"临近，各地医院纷纷加快步伐，地方卫健委也陆续公布本地体重管理门诊的建设进展。 据公开报道，北京已有119家二级及以上医院和76家基层卫生服务中心可提供体重管理服务；广州有63家医院开设了体重管理门诊；浙江全省 249家二级及以上医疗机构已设立体重管理门诊，累计服务患者超过20万人次；四川则有446家医疗机构开设了体重管理或肥胖防治门诊。 目前，外科、内分泌、营养、中医等多个科室纷纷进军减重领域，院内形成了激烈的"赛马"态势，有的医院甚至设立了七八个减重门诊，科室 之间竞 ...

Core Viewpoint - The article discusses the successful listing of TIDE Pharmaceutical on the Hong Kong Stock Exchange, highlighting its market position and future growth plans in the peptide CRDMO sector. Group 1: Company Overview - TIDE Pharmaceutical was officially listed on June 30, with an H-share issue price of HKD 30.60, resulting in a total market capitalization of HKD 43.49 billion [2] - The company focuses on peptide CRDMO services and is the third-largest specialized service provider in this field globally [5] Group 2: Financial Performance - TIDE's revenue for 2022, 2023, and 2024 is projected to be HKD 351 million, HKD 337 million, and HKD 442 million respectively, with net profits of HKD 53.98 million, HKD 48.91 million, and HKD 59.17 million [7] - The company's overseas revenue is expected to grow from HKD 263 million in 2023 to HKD 348 million in 2024, marking a growth rate of 32.4% [7] Group 3: Market Position and Strategy - TIDE plans to use approximately HKD 429 million raised from the IPO to expand facilities in China and the U.S., enhance production capacity, and develop a sales network in Europe [5] - The company is currently collaborating with seven clients on nine GLP-1 new chemical entity projects, covering various stages from preclinical research to clinical trials [10] Group 4: Industry Context - The GLP-1 drug market shows significant potential, with major products like Novo Nordisk's "semaglutide" and Eli Lilly's "tirzepatide" generating annual sales of nearly USD 30 billion and USD 16.5 billion respectively [9] - TIDE's CDMO services generated revenue of HKD 330 million in 2024, accounting for 74.6% of total revenue, with the U.S. market contributing 55% of this revenue [8]

Core Viewpoint - The STEP 5 trial demonstrates that semaglutide 2.4 mg is effective for long-term weight management in obese adults without type 2 diabetes, showing significant and sustained weight loss over a two-year period [2][3][4]. Group 1: Trial Overview - STEP 5 is a phase 3b randomized, double-blind, placebo-controlled trial involving 304 adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) [3][4]. - Participants were assigned to receive either weekly subcutaneous injections of 2.4 mg semaglutide or a placebo, alongside a low-calorie diet and increased physical activity, for 104 weeks [3][4]. - The primary endpoint was the percentage change in weight and the proportion of participants achieving a weight loss of ≥5% by week 104 [3]. Group 2: Weight Loss Results - The semaglutide group experienced a weight loss of -15.2%, compared to -2.6% in the placebo group [4]. - 77.1% of participants in the semaglutide group lost at least 5% of their body weight, while only 34.4% in the placebo group achieved this [4]. Group 3: Safety and Side Effects - Common adverse events associated with semaglutide included nausea, diarrhea, vomiting, constipation, and abdominal pain [6]. - The safety profile of semaglutide in STEP 5 was consistent with previous trials, with 5.9% of patients discontinuing treatment due to adverse events [6]. Group 4: Health Improvements - Significant improvements were observed in waist circumference (-14.4 cm in the semaglutide group vs. -5.2 cm in the placebo group) and systolic blood pressure (-5.7 mmHg vs. -1.6 mmHg) [7]. - Semaglutide also improved various metabolic health markers, including HbA1c, fasting blood glucose, and lipid profiles [7]. Group 5: STEP Trial Context - The STEP program is a comprehensive phase 3 clinical development plan for semaglutide, involving approximately 4,500 overweight or obese adults across multiple trials [8].

以下文章来源于内分泌早知道 ，作者关注肥胖的 内分泌早知道 . 传统观念一直将高热量美食视为肥胖元凶，但加州大学伯克利分校St e pha n Lamme l团队在《自然》期刊发表的最新研究彻底颠覆了这 一认知。该研究题为《神经降压素信号变化驱动肥胖中的快感贬值》，首次揭示进食过程中的愉悦感受对维持健康体重具有不可忽视的 积极作用。令人惊讶的是，即便是火锅、炸鸡、奶茶、蛋糕这类被贴上"垃圾食品"标签的高油高糖食物，其带来的正向饮食体验同样能 成为体重管理的潜在助力。这项突破性研究不仅阐明了肥胖形成的神经生物学机制，更为全球肥胖防治提供了革命性的科学视角。 研究团队通过精密的神经科学实验发现，当大脑接收美食带来的愉悦信号时，会激活特定的神经调控通路，这种正向反馈实际上有助于 维持能量代谢平衡。这一发现完全颠覆了"美味必然导致肥胖"的简单线性思维，将饮食快感从肥胖诱因重新定义为代谢调节的重要环 节。该成果为开发新型肥胖干预策略奠定了理论基础，未来或可通过调节饮食愉悦相关的神经信号通路来实现更科学有效的体重管理。 对于长期陷入"美食诱惑与体重焦虑"矛盾中的现代人来说，这项研究无疑带来了令人振奋的科学启示。 深度分享 ...

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 ▍2025年最新标准体重对照表 很多人总为体重数字焦虑，尤其女性常认为"体重过百"就是肥胖，非得减至100斤以下才算瘦，却忽视了身高差异和整体健康状况。 让我们参考2025年最新标准体重对照表，你或许会发现——自己其实并不胖！ 若一位175cm的男性体重145斤，实际属于标准范围，完全不算肥胖。特别值得注意的是，这类标准表格并不适用于健身人群，因为他们体重普 遍较高但身材紧实。例如同样175cm的健身男性，即使体重达160斤，身材依然可能相当匀称而非肥胖。 对于163cm的女性而言，体重115斤其实仅是标准水平，而非超标。不应为追求"两位数体重"而牺牲健康。同理，这一标准也不适用于健身女 性，她们因肌肉含量高而体重偏大，但身材却往往更加紧致有型。 因此，判断身材是否肥胖，BMI值比单纯体重更具参考价值。 BMI计算公式为：体重(kg)÷身高(m)²。BMI超过24为超重，超过28则属肥胖。对照自身BMI值所在范围即可判断体型状况，不必盲目减重。体 重绝 ...

Core Viewpoint - The article discusses the ongoing patent dispute between Songlei and Conjupro Biotherapeutics, a subsidiary of CSPC Pharmaceutical Group, regarding the validity of a US patent held by Songlei, which is currently under review by the USPTO [1][3]. Group 1: Patent Dispute Details - On June 30, Songlei announced that it was informed on June 24 about Conjupro's request for a Post Grant Review at the USPTO, questioning the validity of specific claims in Songlei's US patent (Patent No: 12,234,236) [1]. - Conjupro's application for "Compound 10" is claimed to be structurally identical to Songlei's "Compound 1," with Songlei asserting that its patent application was submitted over three months prior to Conjupro's [1]. - As of the announcement, the review request is still under examination by the USPTO [1]. Group 2: Background and Implications - Songlei noted that it could not ascertain the specific reasons behind Conjupro's review request, but highlighted that Conjupro had previously sought global licensing discussions for the GLP-1R agonist Compound 1, which Songlei declined [3]. - The patent in question is based on proprietary technology developed by Songlei and is currently being utilized in the development of the candidate drug ASC30, with multiple related molecules protected under various patent systems [4]. - The USPTO officially granted the patent rights to Songlei on February 25, 2025, citing its innovation and non-obviousness compared to existing technologies [4].

深度分享内分泌用药经验、病例剖析、指南专业解读并紧跟国内外内分泌领域前沿进展。 内分泌早知道 . 以下文章来源于内分泌早知道 ，作者关注内分泌的 近年来，随着健康意识的普及，低碳水化合物饮食（LCDs）已成为减肥界的新宠，但其实际效果却引发学界持续争论。传统观点认为 严格控制碳水化合物摄入能有效减重，然而哈佛大学公共卫生学院发表在《JAMA Ne two r k Op e n》的最新研究揭示了一个关键发现： 并非所有低碳水饮食都能帮助减肥，饮食质量才是决定成败的核心因素。这项覆盖1 2万余名受试者的大规模研究指出，以动物蛋白和精 制脂肪为主的低碳水饮食不仅减重效果有限，反而可能导致体重快速反弹。 研究团队通过长达2 4年的追踪观察发现，选择植物性蛋白、健康脂肪和全谷类食物的高质量低碳水饮食者，其体重维持效果显著优于传 统低碳水饮食组。更令人意外的是，那些偏好红肉、加工食品的低碳水饮食者，其体重增长幅度甚至超过了普通饮食人群。这一发现彻 底颠覆了"只要减少碳水就能减肥"的固有认知，证实了食物来源和质量对体重管理的决定性作用。科学家强调，单纯计算碳水化合物含 量而忽视食物营养构成的减肥方式，很可能适得其反。该研究 ...

Core Viewpoint - The article emphasizes the importance of weight management as a critical aspect of public health, particularly in combating chronic non-communicable diseases in China, aligning with the "Healthy China 2030" strategy [3][4]. Group 1: Chronic Disease Prevention and Weight Management - The main risk factors affecting residents' health in China are chronic non-communicable diseases, closely linked to lifestyle habits, dietary structure, and exercise, particularly abnormal weight issues [3]. - The initiative will focus on three main areas: community involvement, knowledge dissemination, and personalized services for weight management [4][5][6]. Group 2: Weight Management Guidelines - Weight is a core indicator of nutrition and health, and both high and low weights can lead to health risks; thus, a preventive approach through balanced diet and regular exercise is essential [7]. - Maintaining an ideal weight significantly reduces the risk of various chronic diseases, making weight management a lifelong commitment [8]. - Regular monitoring of weight and body metrics is crucial, with the Body Mass Index (BMI) being the standard for assessing weight status [10][11]. Group 3: Dietary and Lifestyle Recommendations - Recommended dietary practices include choosing low-calorie, high-nutrition foods, limiting high-calorie items, and developing good eating habits [19]. - Regular physical activity is vital for weight management, with suggestions for integrating exercise into daily routines [20]. - Quality sleep and a positive mindset are important for maintaining a healthy weight, with adults advised to get 7-8 hours of sleep [21]. Group 4: Family Involvement in Weight Management - Weight management should involve the entire family, with each member taking responsibility for their health and supporting one another in adopting healthy lifestyles [23]. Group 5: Intervention and Treatment for Overweight and Obesity - Personalized weight loss goals should be set gradually, with specific recommendations for different BMI categories [24]. - Lifestyle interventions, medical treatments, and innovative management systems are essential for effective weight management [27].

Core Viewpoint - The article discusses the safety and side effects of GLP-1 receptor agonists (GLP-1RA) used in the treatment of type 2 diabetes and obesity, highlighting the importance of understanding potential risks associated with these medications [11][15]. Summary by Sections Side Effects of GLP-1RA - Common side effects of GLP-1RA include nausea, diarrhea, vomiting, constipation, abdominal pain, gastroenteritis, and gastroesophageal reflux disease, which tend to alleviate over time [2]. - Serious health issues may arise, such as increased risk of thyroid cancer, pancreatitis, gallstones, acute kidney injury, retinal damage, and increased heart rate [2]. Comparison of Semaglutide and Tirzepatide - Semaglutide shows good safety in diabetes treatment but can cause gastrointestinal issues, with 17% of patients reporting nausea even at low doses (0.5 mg) [3]. - In clinical trials, 12.2% and 6.4% of patients experienced diarrhea and vomiting, respectively, with a 4% discontinuation rate due to side effects [3]. - Approximately 80% of tirzepatide users report at least one side effect, primarily nausea, diarrhea, constipation, or vomiting, similar to semaglutide [5]. - In trials, 33% of patients on the highest dose of tirzepatide reported nausea, compared to 44% for semaglutide, with diarrhea rates at 23% for tirzepatide and 31% for semaglutide [5]. Safety Warnings and Contraindications - GLP-1RA medications carry a black box warning for potential increased risk of thyroid C-cell tumors, advising against use in patients with a history of medullary thyroid carcinoma or related family history [8]. - Patients with type 2 multiple endocrine neoplasia syndrome, severe allergies to GLP-1RA, or those experiencing pancreatitis should avoid these medications [9]. - Caution is advised for individuals with a history of pancreatitis, severe gastrointestinal diseases, children under 18, and patients with uremia [10]. GLP-1RA and Thyroid Cancer Risk - Animal studies suggest a link between GLP-1RA and the development of medullary thyroid carcinoma, but the association with non-medullary thyroid cancer remains controversial [11]. - Overemphasis on unproven thyroid cancer risks may prevent patients from benefiting from GLP-1RA therapy [11]. - The EMA Safety Committee found that existing evidence does not support a causal relationship between GLP-1RA and thyroid cancer, with randomized controlled trials showing lower incidence rates of thyroid cancer among users [15].

Core Viewpoint - The announcement highlights a significant collaboration between Federal Pharmaceutical and Novo Nordisk, focusing on the development of the drug UBT251, which targets multiple receptors for treating obesity and type 2 diabetes [2][4]. Group 1: Financial Aspects - Federal Pharmaceutical's subsidiary, Federal Biotechnology, received a prepayment of $180 million from Novo Nordisk, equivalent to approximately 1.293 billion RMB after Danish tax deductions [2]. - The collaboration agreement allows Federal Biotechnology to potentially receive a total of $200 million in prepayments and up to $1.8 billion in milestone payments based on the drug's development and commercialization progress [4]. Group 2: Drug Development and Rights - UBT251 is currently in clinical development and operates through a triple mechanism targeting GLP-1, GIP, and glucagon receptors, aimed at treating obesity, type 2 diabetes, and other metabolic diseases [4]. - Novo Nordisk will hold exclusive rights for the development, production, and commercialization of UBT251 globally, excluding Greater China, while Federal Biotechnology retains rights in the Greater China region [4].